Is Diazepam safe for babies and kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Diazepam poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

Diazepam is FDA Pregnancy Category D (positive evidence of human fetal risk; benefits may warrant use in serious or life-threatening conditions). Key concerns: (1) neonatal benzodiazepine withdrawal syndrome — neonates born to mothers using diazepam chronically during pregnancy may develop hypotonia ('floppy infant syndrome'), respiratory depression, feeding difficulties, and withdrawal symptoms (tremors, irritability) after birth; (2) association with cleft palate — early retrospective studies suggested increased risk; subsequent meta-analyses show conflicting results with modest or no increased risk; current FDA labeling retains mention of the concern; (3) maternal CNS depression affecting labor management; (4) active metabolites crossing placenta and accumulating in fetal tissue (diazepam distributes to fetal tissue at concentrations similar to maternal blood). For acute seizure emergencies (status epilepticus) during pregnancy, diazepam remains the treatment of choice — the benefit of seizure control far outweighs fetal risk. For non-emergency use, benzodiazepine alternatives with shorter-acting profiles and less placental transfer may be preferred.